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Abstract. Background. Heart failure is a public health problem and the main cause of 
morbidity and mortality in the world. The goal of the therapy is to reduce symptoms, prevents 
rehospitalization and increases survivability. Objective. To evaluate the adherence to the 
European Society of Cardiology for heart failure treatment at H. Adam Malik Medan 
hospital. Methods. The study was descriptive observational cross sectional design with 
medical record data of heart failure at H. Adam Malik Hospital, using consecutive sampling 
method. The adherence of guidelines was assessed by: (1) drug prescribing (“yes” or “no”), 
and (2) guideline adherence indicator (GAI), both GAI-3 or GAI-5, by calculating the 
proportion as the number of drugs prescribed by number of drugs indicated to the ESC 
guidelines. Results. From research, the predominant GAI-3 and GAI-5 were High, which 
were 54.9% and 59.5%, respectively. The recommended drug used based on indications were 
ACE-i / ARB (89.1%), beta-blockers (83.4%), MRA (73.6%), diuretics (93.7%), and digitalis 
(20,8%). Conclusion. The predominant category in adherence to the ESC heart failure 
treatment guidelines based on GAI-3 and GAI-5 is High.  
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1 Introduction 
Heart failure is a group of clinical syndromes which is caused by structural or functional heart 
disorders which disrupt the ability of the ventricle to fill or eject blood [1,2]. The prevalence of 
heart failure in Indonesia and the world is still high [3,4]. 
Heart failure therapy must be done according to the suitable treatment to increase the success of 
treatment, quality of life, and reduce both the mortality and morbidity of the patient [3,4]. 
Appropriate therapy for this condition has been proven effective in reducing the incidence of heart 
failure [5]. 
The guideline for heart failure treatment had been released to help doctors in giving the best 
treatment for the patient The guideline was released by the European Society of Cardiology (ESC) 
which contain the consensus for pharmacological and non-pharmacological criteria [6]. The 
ESC’s  treatment recommendation for heart failure patients are angiotensin converting enzyme 
inhibitor (ACE-I) or angiotensin receptor blocker (ARB), beta blockers, and mineralcorticoid 
receptor antagonist (MRA) for heart failure therapy. Diuretics could be used in combination to 
relieve symptoms and signs of congestion [4]. 
This study is a continuation from a previous study conducted by Andika Sitepu and Khalis 
Hamdani during the period of January 2013 - June 2014. The aim of this study is to see whether 
or not there is a difference in obedience of the ESC guideline on heart failure patients in Adam 
Malik Central General Hospital, Medan. 
2 Methods 
This is descriptive observational study which was conducted on July – December 2019. This study 
uses medical record data of 284 patients chronic heart failure with reduced ejection fraction that 
meets the inclusion and exclusion criteria at the Haji Adam Malik General Hospital Medan from 
January 2015 - December 2018. The samples were collected by consecutive sampling method 
from 2015 - 2018 patients medical record until get a total of 284 patients. 
Inclusion criteria were: (i) age over 18 years, (ii) outpatient with chronic heart failure, (iii) reduced 
ejection fraction ≤ 40%. We excluded Patient presenting with: (i) Asthma, (ii) COPD (Chronic 
Obstruction Pulmonary Disease) acute exacerbation, (iii) symptomatic hypotension (systolic 
blood pressure < 90 mmHg), (iv) severe aortic stenosis, (v) severe mitral stenosis, (vi) renal artery 
stenosis and (vii) hyperkalemia.  
The guidelines adherence indicator (GAI) was used to evaluate physician adherence to the ESC 
guidelines for the treatment of chronic heart failure with reduces ejection fraction6. The GAI 
specified into two different groups. GAI-3 consists of ACE-I or ARB, beta-blocker, and MRA, 
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considering the substantial evidence to improve clinical outcome. The GAI-5, in addition to the 
three pharmacological classes, considered the use of diuretics and digitalis, which predominantly 
targets improving symptoms. Furthermore, GAI-3 was three categories; these were low adherence 
(0 or 33%), moderate adherence (67%), and high adherence (100%).In the same way, GAI-5 was 
three categories; these were low adherence (0-20%), moderate adherence (40-60%), and high 
adherence (80-100%). 
3 Results 
Table 1 Patients characteristics  
Characteristics Population (n = 284) Percentage (%) 
Gender :   
Male 221 77,8 
Female 63 22,2 
Age :   
<50 tahun 91 32,0 
50 - 75 tahun 185 65,1 
>75 tahun 8 2,8 
Table 1 show patients’ heart failure characteristics that, male tend to develop heart failure than 
female from 284 patients diagnosed with heart failure. By age, the peak incidence of HCC was in 
50-75 years (65,1%). For <50 years, there are 91 patients diagnosed with heart failure (32,0%), 
and >75 years, there are 8 patients diagnosed with heart failure (2,8%). 
Table 2 Pharmacology treatments for heart failure 
Medication Population (n = 284) 
Captopril 148 (52,1) 
Ramipril 53 (18,7) 
Valsartan 42 (14,8) 
Candensartan 9 (3,2) 
Irbesartan 1 (0,4) 
Bisoprolol 235 (82,7) 
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Carvedilol 2 (0,7) 
Spironolakton 209 (73,6) 
Furosemid 266 (93,7) 
Digoxin 59 (20,8) 
Table 2 shows that the prescription rates for ACE-I/ARBs were 89,2%, followed by beta-blockers 
(83,4%), and MRAs (73,6%). In addition to the three substance classes, the prescription rates 
diuretic was the highest (93,7%) and the use of digitalis was 20,8%. 
Table 3 guideline adherence indicators 
 Low, n (%) Moderate, n (%) High, n (%) Median (IQR) 
GAI-3 25 (8,8) 103 (36,3) 156 (54,9) 100% (67-100%) 
GAI-5 4 (1,4) 111 (39,1) 169 (59,5) 80% (60-80%) 
Table 3 shows that the predominant category for both GAI-3 and GAI-5 were high, 156 (54.9%) 
and 169 (59.5%) respectively. Table 3 also shows the median values of both GAI-3 (100%) and 
GAI-5 (80%) were also calculated to determine the overall quality of pharmacology. 
4 Discussion 
From the study, we get that heart failure is more dominant in male than in female. This is similar 
as the other studies from Sitepu & Hamdani, Jensen et al., and Savaresa & Lund [6,8,9]. This 
study also shows that the incidence of heart failure increase corresponding with the increase of 
age. The result is similar with previous study from Sitepu & Hamdani, Lee et al., and Riskesdas 
[6,10,11]. Despite that, due to lower life expectancy in Indonesia [10], the average age of patients 
is younger compared to the other studies. 
ESC guidelines recommend neurohormonal antagonist heart failure drugs that must be given to 
heart failure patients with reduced ejection fractions namely ACE-I/ARB, beta-blockers, and 
MRA [12]. The prescription rates for ACE-I/ARBs was 89,2%, followed by beta-blockers 
(83,4%), and MRAs (73,6%). The result shows improvement of prescription rates for 
neurohormonal antagonist heart failure treatment from previous study [6]. Diuretics were the most 
frequently prescribed in this study, with 93,7%, this finding in line with previous study [6]. Other 
studies also reported the use of diuretics as the most commonly prescribed drugs [13,14]. In our 
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study, high prescription diuretic drugs may be due to most patients experiencing signs of 
congestion which is dyspnea. 
The adherence to the ESC guidelines was associated with better prognosis, improved clinical 
outcome, fewer cardiovascular hospitalizations and delayed time to rehospitalization [6]. In our 
study, we found that the predominant categories of GAI-3 (54,9%) and GAI-5 (59,5%) were high, 
similar to the other study [14,15]. The adherence of both GAI-3 and GAI-5 based on ESC 
guidelines has increased from moderate to high compared to previous studies [6]. The median 
values of GAI-3 and GAI-5 were also used to evaluate the pharmacotherapy quality [14]. This 
results shows a significant improvement of median values of GAI-3 and GAI-5 from previous 
studies. This might be possible because the distribution of drugs in the Adam Malik General 
Hospital was sufficient. 
5 Conclusion 
This is the follow-up study from previous study conducted by Sitepu and Hamdani. In our study, 
the adherence to ESC guidelines for the treatment of heart failure has improved significantly 
compared to previous study, from moderate to high adherence. 
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